Swiss healthcare company Roche Holding AG (Roche) (SIX:ROG) has said that its first quarter 2022 sales rose by 10% on strong US demand for rapid COVID-19 antigen tests, Reuters news agency reported on Monday.
Roche's quarterly sales rose to CHF16.44bn, up from CHF14.93bn in the first quarter of the prior year.
This was slightly above a market consensus of about CHF16bn.
The company's diagnostics division accounted for most of the positive surprise, reporting sales growth of 24% to CHF5.3bn on usage of its COVID-19 tests and cardiac tests.
First quarter sales were also boosted by drugs including Ocrevus against multiple sclerosis, as well as Hemlibra against haemophilia.
Ocrevus revenues gained 18% to reach CHF1.45bn, while Hemlibra sales jumped 30% to CHF853m.
This offset a decline in established off-patent cancer medicines Herceptin, Avastin and Rituxan due to cheaper rival products.
Roche reiterated that it expected currency-adjusted 2022 sales to be flat or grow in the low-single-digit percentage range, below last year's 9% gain.
It also reaffirmed that sales of COVID-19 medicines and diagnostics would decrease by about CHF2bn in 2022 to about CHF5bn.
(EUR1.00=CHF1.03)
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy